{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bandes oligoclonales : Questions médicales les plus fréquentes",
"headline": "Bandes oligoclonales : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bandes oligoclonales : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-15",
"dateModified": "2025-04-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bandes oligoclonales"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Marqueurs biologiques",
"url": "https://questionsmedicales.fr/mesh/D015415",
"about": {
"@type": "MedicalCondition",
"name": "Marqueurs biologiques",
"code": {
"@type": "MedicalCode",
"code": "D015415",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.101"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bandes oligoclonales",
"alternateName": "Oligoclonal Bands",
"code": {
"@type": "MedicalCode",
"code": "D043025",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Luisa María Villar",
"url": "https://questionsmedicales.fr/author/Luisa%20Mar%C3%ADa%20Villar",
"affiliation": {
"@type": "Organization",
"name": "Ramon y Cajal Hospital of Madrid, Spain."
}
},
{
"@type": "Person",
"name": "Wei Qiu",
"url": "https://questionsmedicales.fr/author/Wei%20Qiu",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address: qiuwei120@vip.163.com."
}
},
{
"@type": "Person",
"name": "Alexander Y Lau",
"url": "https://questionsmedicales.fr/author/Alexander%20Y%20Lau",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: alexlau@cuhk.edu.hk."
}
},
{
"@type": "Person",
"name": "Hongjun Hao",
"url": "https://questionsmedicales.fr/author/Hongjun%20Hao",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Neuroimmunology Laboratory, Peking University First Hospital, Beijing, China."
}
},
{
"@type": "Person",
"name": "Carmen M Cabrera",
"url": "https://questionsmedicales.fr/author/Carmen%20M%20Cabrera",
"affiliation": {
"@type": "Organization",
"name": "Immunology Section, University General Hospital of Ciudad Real, Ciudad Real, Spain; Faculty of Medicine of Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain. Electronic address: carmenmcabrera@gmail.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Incident commander decision making: Quantitative evaluation of instantaneous and considered decisions.",
"datePublished": "2023-09-23",
"url": "https://questionsmedicales.fr/article/37748355",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.apergo.2023.104139"
}
},
{
"@type": "ScholarlyArticle",
"name": "Understanding the processes behind the decisions - GPs and complex multimorbidity decision making.",
"datePublished": "2022-06-28",
"url": "https://questionsmedicales.fr/article/35761167",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12875-022-01781-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "For which decisions is Shared Decision Making considered appropriate? - A systematic review.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36220675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pec.2022.09.015"
}
},
{
"@type": "ScholarlyArticle",
"name": "A theory of oral healthcare decision-making in Appalachia.",
"datePublished": "2024-05-20",
"url": "https://questionsmedicales.fr/article/38768179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0303831"
}
},
{
"@type": "ScholarlyArticle",
"name": "Confidence and risky decision-making in gambling disorder.",
"datePublished": "2023-08-21",
"url": "https://questionsmedicales.fr/article/37603457",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1556/2006.2023.00041"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Marqueurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D015415"
},
{
"@type": "ListItem",
"position": 4,
"name": "Bandes oligoclonales",
"item": "https://questionsmedicales.fr/mesh/D043025"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bandes oligoclonales - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bandes oligoclonales",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bandes oligoclonales",
"description": "Comment détecte-t-on les bandes oligoclonales ?\nQuelles maladies sont associées aux bandes oligoclonales ?\nQuel est le rôle des bandes oligoclonales dans le diagnostic ?\nLes bandes oligoclonales sont-elles toujours présentes dans les maladies ?\nQuel test est utilisé pour analyser les bandes oligoclonales ?",
"url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Decision+Making&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bandes oligoclonales",
"description": "Quels symptômes peuvent indiquer la présence de bandes oligoclonales ?\nLes bandes oligoclonales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les maladies ?\nLes symptômes sont-ils toujours présents avec des bandes oligoclonales ?\nQuels tests neurologiques complètent l'analyse des bandes ?",
"url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Decision+Making&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bandes oligoclonales",
"description": "Peut-on prévenir les maladies liées aux bandes oligoclonales ?\nQuels facteurs de risque sont associés aux maladies neurologiques ?\nL'alimentation influence-t-elle le risque de maladies neurologiques ?\nLe stress a-t-il un impact sur ces maladies ?\nDes vaccinations peuvent-elles prévenir ces maladies ?",
"url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Decision+Making&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bandes oligoclonales",
"description": "Quel traitement est recommandé pour les maladies associées ?\nLes bandes oligoclonales nécessitent-elles un traitement direct ?\nQuels médicaments sont utilisés pour la sclérose en plaques ?\nLes traitements sont-ils efficaces contre les bandes ?\nY a-t-il des traitements expérimentaux pour ces conditions ?",
"url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Decision+Making&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bandes oligoclonales",
"description": "Quelles complications peuvent survenir avec la sclérose en plaques ?\nLes bandes oligoclonales entraînent-elles des complications ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme des maladies neurologiques ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Decision+Making&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bandes oligoclonales",
"description": "Quels sont les principaux facteurs de risque pour la sclérose en plaques ?\nLe tabagisme est-il un facteur de risque ?\nL'exposition à des virus influence-t-elle le risque ?\nLe climat joue-t-il un rôle dans le risque de sclérose en plaques ?\nL'activité physique peut-elle réduire le risque ?",
"url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Decision+Making&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on les bandes oligoclonales ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont détectées par électrophorèse du liquide céphalorachidien."
}
},
{
"@type": "Question",
"name": "Quelles maladies sont associées aux bandes oligoclonales ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont souvent liées à la sclérose en plaques et d'autres maladies neurologiques."
}
},
{
"@type": "Question",
"name": "Quel est le rôle des bandes oligoclonales dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles aident à confirmer des diagnostics neurologiques en indiquant une réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Les bandes oligoclonales sont-elles toujours présentes dans les maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur présence n'est pas systématique et dépend de la maladie et de son stade."
}
},
{
"@type": "Question",
"name": "Quel test est utilisé pour analyser les bandes oligoclonales ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'électrophorèse sur gel est couramment utilisée pour analyser les bandes oligoclonales."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer la présence de bandes oligoclonales ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes neurologiques comme des troubles de la vision ou des engourdissements."
}
},
{
"@type": "Question",
"name": "Les bandes oligoclonales causent-elles des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont un indicateur de maladie, mais ne causent pas de symptômes directement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon les maladies ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon la maladie sous-jacente, comme la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents avec des bandes oligoclonales ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas nécessairement, certaines personnes peuvent avoir des bandes sans symptômes visibles."
}
},
{
"@type": "Question",
"name": "Quels tests neurologiques complètent l'analyse des bandes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des IRM et des tests neurologiques peuvent compléter l'analyse des bandes oligoclonales."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux bandes oligoclonales ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux maladies neurologiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge, le sexe et des antécédents familiaux peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de maladies neurologiques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut réduire le risque, mais des études sont nécessaires."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur ces maladies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut aggraver les symptômes, mais son rôle exact dans la maladie est complexe."
}
},
{
"@type": "Question",
"name": "Des vaccinations peuvent-elles prévenir ces maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les maladies associées."
}
},
{
"@type": "Question",
"name": "Quel traitement est recommandé pour les maladies associées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements varient, mais incluent souvent des immunomodulateurs pour la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "Les bandes oligoclonales nécessitent-elles un traitement direct ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne nécessitent pas de traitement direct, mais indiquent une maladie à traiter."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour la sclérose en plaques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme l'interféron et le natalizumab sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre les bandes ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements visent la maladie sous-jacente, pas les bandes elles-mêmes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour ces conditions ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements expérimentaux sont en cours d'évaluation pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la sclérose en plaques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles de la mobilité, de la vision et des fonctions cognitives."
}
},
{
"@type": "Question",
"name": "Les bandes oligoclonales entraînent-elles des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ne causent pas de complications directement, mais indiquent une maladie à risque."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en limitant les activités quotidiennes et sociales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme des maladies neurologiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent inclure des handicaps physiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour la sclérose en plaques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe féminin, et des antécédents familiaux de la maladie."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de développer des maladies neurologiques."
}
},
{
"@type": "Question",
"name": "L'exposition à des virus influence-t-elle le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le climat joue-t-il un rôle dans le risque de sclérose en plaques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que le risque est plus élevé dans les régions éloignées de l'équateur."
}
},
{
"@type": "Question",
"name": "L'activité physique peut-elle réduire le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activité physique régulière peut contribuer à réduire le risque de maladies neurologiques."
}
}
]
}
]
}
The Incident Commander (IC) decision-making process has previously been modeled primarily by qualitative evaluation methods, which has made it difficult to generalize an objective model. In this study...
Complex multimorbidity, defined either as three or more chronic conditions affecting three or more different body systems or by the patients General Practitioner (GPs), is associated with various adve...
To identify decision characteristics for which SDM authors deem SDM appropriate or not, and what arguments are used....
We applied two search strategies: we included SDM models from an earlier review (strategy 1) and conducted a new search in eight databases to include papers other than describing an SDM model, such as...
From the 92 included papers, we identified 18 decision characteristics for which authors deemed SDM appropriate, including preference-sensitive, equipoise and decisions where patient commitment is nee...
The findings of this review show the broad range of decision characteristics for which authors deem SDM appropriate, the ambiguity of some, and potential limits of SDM....
The findings can stimulate clinicians to (re)consider pursuing SDM in situations in which they did not before. Additionally, it can inform SDM campaigns and educational programs as it shows for which ...
People make oral healthcare decisions regardless of having partial information, misinformation, sources that deliberately mislead, or information that is culturally influenced. This is particularly tr...
The researchers used a grounded theory qualitative study design to explain data for a theory of OHDA. Participants from Appalachia, in 20-minute interviews, provided insights into concepts that influe...
Five overarching concepts that embody OHDA were discovered: Affect (Level of Pain/Emotion/Stress involvement), Awareness, Trust/belief, Resources, and Risk Perception. All participants discussed the i...
To influence a person's OHDA, public health officials and researchers need to address the person's affect, level of awareness, trust/belief, available resources, and risk perception. Social media is v...
People with Gambling Disorder (GD) often make risky decisions and experience cognitive distortions about gambling. Moreover, people with GD have been shown to be overly confident in their decisions, e...
We used data from our previous mixed-gamble study, in which participants were given the choice of a certain option or a 50/50 gamble with potential gains or losses, after which they rated their confid...
While HCs were more confident when making certain than risky choices, GD patients were specifically more confident when making risky choices than certain choices. Notably, relative to HCs, confidence ...
The current findings highlight the potential relevance of confidence and "regret" as cognitive mechanisms feeding into excessive risk-taking as seen in GD. Moreover, this study adds to the limited pre...
Pubertal development is a potential trigger for increases in risk-taking behaviours during adolescence. Here, we sought to investigate the relationship between puberty and neural activation during ris...
Self-control can be defined as making choices in accordance with long-term, rather than short-term, patterns of behavior. Rachlin (2016) suggested a novel technique to enhance self-control, by which i...
Patients with anorexia nervosa (AN) show impaired decision-making ability, but it is still unclear if this is a trait marker (i.e., being associated with AN at any stage of the disease) or a state par...
Ninety-one patients with acute AN (A-AN), 90 unaffected relatives (UR), 23 patients remitted from AN (R-AN), and 204 healthy controls (HC) carried out the Iowa gambling task (IGT). Prospective valence...
Patients with A-AN had lower performance at the IGT (...
Alteration of decision-making ability did not show endophenotypic features. Impaired decision-making seems a state-associated characteristic of AN, resulting from the interplay between trait-associate...
Although traditional medical ethics focuses on the dyadic doctor-patient relationship, when the patient is a child, the relationship is triadic, meaning it involves the patient, the parent(s), and the...
Despite advances in prevention, detection, and treatment, cardiovascular disease is a leading cause of mortality and represents a major health problem worldwide. Artificial intelligence and machine le...